Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1931 1
1945 1
1946 2
1947 1
1948 2
1949 2
1950 1
1951 1
1952 3
1953 8
1954 5
1955 4
1956 5
1957 6
1958 8
1959 5
1960 7
1961 9
1962 6
1963 8
1964 8
1965 9
1966 4
1967 6
1968 10
1969 8
1970 14
1971 7
1972 10
1973 10
1974 12
1975 9
1976 14
1977 8
1978 6
1979 11
1980 13
1981 15
1982 19
1983 16
1984 16
1985 21
1986 21
1987 23
1988 32
1989 28
1990 24
1991 28
1992 31
1993 37
1994 42
1995 37
1996 47
1997 37
1998 43
1999 40
2000 41
2001 49
2002 49
2003 59
2004 58
2005 64
2006 81
2007 60
2008 89
2009 105
2010 125
2011 125
2012 133
2013 145
2014 153
2015 181
2016 153
2017 157
2018 164
2019 173
2020 185
2021 237
2022 219
2023 227
2024 72

Text availability

Article attribute

Article type

Publication date

Search Results

3,531 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for keller m
Search for Keiller M instead (3 results)
Third-party virus specific T cells for the treatment of double stranded DNA viral reactivation and PTLD after solid organ transplant.
Khoury R, Grimley MS, Nelson AS, Leemhuis T, Cancelas JA, Cook E, Wang Y, Heyenbruch D, Bollard CM, Keller MD, Hanley PJ, Lutzko C, Pham G, Davies SM, Rubinstein JD. Khoury R, et al. Among authors: keller md. Am J Transplant. 2024 Apr 19:S1600-6135(24)00280-6. doi: 10.1016/j.ajt.2024.04.009. Online ahead of print. Am J Transplant. 2024. PMID: 38643944
Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment.
Keller MD, Hanley PJ, Chi YY, Aguayo-Hiraldo P, Dvorak CC, Verneris MR, Kohn DB, Pai SY, Dávila Saldaña BJ, Hanisch B, Quigg TC, Adams RH, Dahlberg A, Chandrakasan S, Hasan H, Malvar J, Jensen-Wachspress MA, Lazarski CA, Sani G, Idso JM, Lang H, Chansky P, McCann CD, Tanna J, Abraham AA, Webb JL, Shibli A, Keating AK, Satwani P, Muranski P, Hall E, Eckrich MJ, Shereck E, Miller H, Mamcarz E, Agarwal R, De Oliveira SN, Vander Lugt MT, Ebens CL, Aquino VM, Bednarski JJ, Chu J, Parikh S, Whangbo J, Lionakis M, Zambidis ET, Gourdine E, Bollard CM, Pulsipher MA. Keller MD, et al. Nat Commun. 2024 Apr 18;15(1):3258. doi: 10.1038/s41467-024-47057-2. Nat Commun. 2024. PMID: 38637498 Free PMC article. Clinical Trial.
Illuminating Neuropeptide Y Y4 Receptor Binding: Fluorescent Cyclic Peptides with Subnanomolar Binding Affinity as Novel Molecular Tools.
Gleixner J, Kopanchuk S, Grätz L, Tahk MJ, Laasfeld T, Veikšina S, Höring C, Gattor AO, Humphrys LJ, Müller C, Archipowa N, Köckenberger J, Heinrich MR, Kutta RJ, Rinken A, Keller M. Gleixner J, et al. Among authors: keller m. ACS Pharmacol Transl Sci. 2024 Mar 20;7(4):1142-1168. doi: 10.1021/acsptsci.4c00013. eCollection 2024 Apr 12. ACS Pharmacol Transl Sci. 2024. PMID: 38633582
Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.
de Boniface J, Filtenborg Tvedskov T, Rydén L, Szulkin R, Reimer T, Kühn T, Kontos M, Gentilini OD, Olofsson Bagge R, Sund M, Lundstedt D, Appelgren M, Ahlgren J, Norenstedt S, Celebioglu F, Sackey H, Scheel Andersen I, Hoyer U, Nyman PF, Vikhe Patil E, Wieslander E, Dahl Nissen H, Alkner S, Andersson Y, Offersen BV, Bergkvist L, Frisell J, Christiansen P; SENOMAC Trialists’ Group; SENOMAC Trialists' Group. de Boniface J, et al. N Engl J Med. 2024 Apr 4;390(13):1163-1175. doi: 10.1056/NEJMoa2313487. N Engl J Med. 2024. PMID: 38598571 Clinical Trial.
Mending RAG2: gene editing for treatment of RAG2 deficiency.
Hicks ED, Keller MD. Hicks ED, et al. Among authors: keller md. Blood Adv. 2024 Apr 9;8(7):1817-1819. doi: 10.1182/bloodadvances.2023012079. Blood Adv. 2024. PMID: 38592712 Free PMC article. No abstract available.
3,531 results